ScreenerHero

XLO Xilio Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · xiliotx.com
9.010USD+0.11%Mkt Cap: 59.29M $P/E: —

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap59.29M USD
Enterprise Value-70.52M USD
Revenue (TTM)64.09M USD
Gross Profit53.30M USD
Net Income (TTM)-35.04M USD
Revenue/Share9.74 USD
Last Price9.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.52
PEG—
EV/EBITDA2.35
EV/Revenue-1.10
P/S0.92
P/B1.16
EPS (TTM)-0.60
EPS (Forward)-0.58
52W Range
6.46841% of range12.74
52W High12.74 USD
52W Low6.468 USD
Profitability
Gross Margin83.16%
Oper. Margin-18.68%
EBITDA Margin-46.86%
Profit Margin-80.05%
ROE-99.33%
ROA-22.65%
Growth
Revenue Growth131.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.99M USD
CapEx (TTM)518.00K USD
FCF Margin-58.61%
FCF Yield-63.36%
Net Debt-129.74M USD
Net Debt/EBITDA4.32
Balance Sheet
Debt/Equity0.20
Current Ratio4.25
Quick Ratio4.15
Book Value/Sh7.79 USD
Cash/Share20.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateMar 16, 2026
Analyst Consensus
Rating—
Target (Mean)20.00 USD
Upside (mean)+122.0%
Target Range20.00 USD – 20.00 USD
# Analysts1
Ownership
Shares Out.6.58M
Float3.40M
Insiders25.98%
Institutions50.16%
Short Interest
Short Ratio37.0d
Short % Float7.01%
Short % Out.6.28%
Shares Short412.96K
Short (prev mo.)421.92K
Technical
SMA 509.073 (-0.7%)
SMA 2008.578 (+5.0%)
Beta-0.12
S&P 52W Chg16.45%
Avg Vol (30d)9.61K
Avg Vol (10d)7.47K
Technical Indicators
RSI (14)49.8
MACD-0.0025
MACD Signal-0.0058
MACD Hist.+0.0032
BB Upper9.124 USD
BB Middle8.996 USD
BB Lower8.869 USD
BB Width2.84%
ATR (14)0.3231 USD
Vol Ratio (20d)0.11x